Suzuken H1 Operating Profit Falls 20% to ¥13.6 Billion as Purchase Prices and Outsourcing Costs Outpace 5.1% Sales Growth

Suzuken's revenue rose 5.1% to ¥1,281,025 million in the six months to September, helped by a growing prescription-drug market and new specialty medicines, but operating profit fell 20.0% to ¥13,561 million as purchase prices and inflation-driven outsourcing costs climbed. Net profit attributable to owners of the parent declined 20.1% to ¥12,974 million, and the full-year forecast was left unchanged.

Suzuken H1 FY3/2027 earnings summary

Specialty drugs lift sales, costs squeeze margins

Suzuken Co., Ltd. (TSE: 9987), the Nagoya-based pharmaceutical wholesaler, published consolidated results for the first half of FY3/2027, April 1 to September 30, 2026, on November 12, 2026 under Japanese GAAP. Revenue rose 5.1% to ¥1,281,025 million, operating profit fell 20.0% to ¥13,561 million, ordinary profit fell 14.9% to ¥15,343 million and profit attributable to owners of the parent fell 20.1% to ¥12,974 million. The company said it kept working to secure appropriate margins and to review and contain selling, general and administrative expenses, but higher purchase prices for drugs and rising operating costs such as outsourcing fees, which it attributed to inflation, more than offset the sales gain.

From the first quarter Suzuken reorganised its reporting into six segments, and the prior-year figures have been restated on the new basis. Pharmaceutical Wholesale, which now also includes specialty-drug distribution, grew revenue 5.3% to ¥1,236,309 million while its operating profit fell 9.8% to ¥12,339 million on higher purchase and logistics costs. Digital Business lifted sales 39.6% to ¥1,690 million on promotion revenue from its AI-MS avatar service, but upfront spending on new services widened its operating loss to ¥855 million from ¥59 million. Logistics lifted operating profit 32.7% to ¥1,811 million after repricing contracts. Healthcare Product Development's operating profit fell 76.2% to ¥284 million because of higher manufacturing costs, research spending on the acromegaly drug paltusotine and the suspension of its Kumamoto plant after the earthquake of July 28, 2026, for which the company booked an extraordinary loss of ¥354 million and said the full impact is still being assessed. Community Healthcare & Nursing Care Support swung to an operating loss of ¥152 million.

Interim dividend raised, shares split two-for-one

Total assets rose to ¥1,217,937 million from ¥1,155,766 million at March 31, 2026, and the equity ratio slipped from 36.0% to 34.4%. Suzuken paid an interim dividend of ¥60, up from ¥50. It split its shares two-for-one with effect from October 1, 2026; the year-end dividend forecast of ¥30 is stated on the post-split basis and is equivalent to ¥60 before the split, or ¥120 for the full year against ¥100 for FY3/2026. Per-share profit of ¥96.07 is restated as if the split had applied from the start of the prior year. The board also enlarged the shareholder benefit for holders of 100 or more shares to ¥5,000 in value from ¥3,000 for the rest of the current medium-term plan.

Guidance unchanged

Suzuken left its FY3/2027 forecast unchanged at revenue of ¥2,563,000 million (+3.1%), operating profit of ¥31,200 million (−14.2%), ordinary profit of ¥34,300 million (−13.7%) and profit attributable to owners of ¥25,000 million (−34.4%). The first half delivered 50.0% of the revenue forecast and 43.5% of the operating-profit forecast.

Suzuken Co., Ltd. — H1 FY3/2027 (April 1 – September 30, 2026), Japanese GAAP, consolidated. Balance-sheet rows compare September 30, 2026 with March 31, 2026; guidance and dividend rows are full-year FY3/2027 against FY3/2026. "—" indicates a figure not disclosed.
MetricH1 FY3/2027H1 FY3/2026Change
Revenue (¥ million)1,281,0251,219,440+5.1%
Operating profit (¥ million)13,56116,958−20.0%
Ordinary profit (¥ million)15,34318,032−14.9%
Net profit attrib. to owners of parent (¥ million)12,97416,241−20.1%
EPS (¥)96.07114.05−15.8%
Pharmaceutical Wholesale — revenue (¥ million)1,236,3091,173,922+5.3%
Pharmaceutical Wholesale — segment profit (¥ million)12,33913,682−9.8%
Digital Business — revenue (¥ million)1,6901,210+39.6%
Digital Business — segment profit (¥ million)−855−59loss widened
Logistics — revenue (¥ million)28,92127,890+3.7%
Logistics — segment profit (¥ million)1,8111,364+32.7%
Healthcare Product Development — revenue (¥ million)25,69925,477+0.9%
Healthcare Product Development — segment profit (¥ million)2841,192−76.2%
Community Healthcare & Nursing Care Support — revenue (¥ million)45,71946,483−1.6%
Community Healthcare & Nursing Care Support — segment profit (¥ million)−152411profit to loss
Total assets (¥ million)1,217,9371,155,766+5.4%
Net assets (¥ million)419,005416,012+0.7%
Equity ratio34.4%36.0%−1.6 pt
FY3/2027 guidance — revenue (¥ million)2,563,000—+3.1%
FY3/2027 guidance — operating profit (¥ million)31,200—−14.2%
FY3/2027 guidance — ordinary profit (¥ million)34,300—−13.7%
FY3/2027 guidance — net profit (¥ million)25,000—−34.4%
Interim dividend per share (¥)60.0050.00+20.0%

JapanStockPulse provides informational content only and does not constitute investment advice. Figures are taken from the company's published earnings short report and may be subject to subsequent revision.